These data indicate that, although OVCAR4-PR2 is resistant to platinum and paclitaxel and is characterized by upregulation of drug resistance and cancer stem cell markers, such as tau, ALDH1A1, and CD44, it did not gain a true cancer stem cell phenotype in the process of its transformation. The gene discussed is CD44; the disease is cancer.